Adjuvant TACE combined with tislelizumab in patients with resected hepatocellular carcinoma at high risk of recurrence: An open-label, multicenter, phase II trial

被引：0
|
作者：
Ma, T. [1 ]
Wen, L. [1 ]
Zhang, J. [2 ]
Zhang, Z. [3 ]
Zeng, Y. [4 ]
Wang, Y. [5 ]
Zheng, J. [6 ]
Liang, T. [1 ]
机构：
[1] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hepatobiliary & Pancreat Surg, Hangzhou, Peoples R China
[2] China Med Univ, Affiliated Hosp 1, Clin Med, Shenyang, Peoples R China
[3] Shandong Univ, Qilu Hosp, Dept Hepatobiliary Surg, Jinan, Peoples R China
[4] Fujian Med Univ, Mengchao Hepatobiliary Hosp, Dept Hepatobiliary & Pancreat Surg, Fuzhou, Peoples R China
[5] Tianjin Third Cent Hosp, Dept Hepatobiliary Surg, Tianjin, Peoples R China
[6] Hainan Gen Hosp, Dept Hepatobiliary & Pancreat Surg, Haikou, Hainan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.259
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
239P
引用
收藏
页码：S1494 / S1494
页数：1
相关论文
共 50 条
  • [41] TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial
    Erhardt, Andreas
    Kolligs, Frank
    Dollinger, Matthias
    Schott, Eckart
    Wege, Hennig
    Bitzer, Michael
    Gog, Christiane
    Lammert, Frank
    Schuchmann, Markus
    Walter, Clemens
    Blondin, Dirk
    Ohmann, Christian
    Haussinger, Dieter
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (05) : 947 - 954
  • [42] Transarterial chemoembolization (TACE) combined with camrelizumab and apatinib versus TACE alone in the treatment of unresectable hepatocellular carcinoma eligible for embolization: A multicenter, open-label, randomized, phase 2 study (CAP-ACE).
    Zhu, Haidong
    Fan, Weijun
    Ji, Jian-Song
    Yang, Wei-Zhu
    Zhao, Chang
    Huang, Ming
    Wang, Song
    Li, Yu-Liang
    Shao, Guo-Liang
    Cheng, Hong-Tao
    Zeng, Yong-Yi
    Lv, Weifu
    Xu, Hao
    Lu, Ligong
    Shao, Hai-Bo
    Zhao, Xu-Ya
    Gu, Shan-Zhi
    Lin, Hai-Lan
    Zheng, Wen-Heng
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : LBA522 - LBA522
  • [43] The efficacy and safety of tislelizumab as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after radical reaction
    Peng, N.
    Su, J-Y.
    Liu, S.
    Li, L.
    Ma, L.
    Zhong, J-H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1487 - S1487
  • [44] A multicenter, randomized, controlled, phase II trial exploring adjuvant combined therapy of apatinib and SHR-1210 (anti-PD-1), in patients with hepatocellular carcinoma at high risk of recurrence after radical resection
    Yan, S.
    Zhang, Y.
    Bi, X.
    Zhao, J.
    Du, S.
    Huang, Z.
    Zhang, Y.
    Liu, D.
    Li, Z.
    Zhou, J.
    Cai, J.
    Zhao, H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [45] TIDE: adjuvant tislelizumab plus donafenib combined with transarterial chemoembolization for high-risk hepatocellular carcinoma after surgery: protocol for a prospective, single-arm, phase II trial
    Qi, Weili
    Peng, Wei
    Qi, Xin
    Qiu, Zhancheng
    Wen, Tianfu
    Li, Chuan
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [46] A retrospective study of the efficacy and safety of donafenib combined with TACE as adjuvant therapy in patients with high-risk recurrence factors after hepatocellular carcinoma surgery
    Zou, Qifei
    Yuan, Shengxian
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [47] A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: Final results
    Gruenwald, V.
    Wilkens, L.
    Gebel, M.
    Greten, T. F.
    Kubicka, S.
    Ganser, A.
    Manns, M. P.
    Malek, N. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [48] Thermal ablation plus toripalimab in patients with advanced hepatocellular carcinoma: Phase I results from a multicenter, open-label, controlled phase I/II trial (IR11330)
    Shi, L.
    Zhou, C.
    Long, X.
    Li, H.
    Chen, C.
    Peng, C.
    Li, P.
    Li, J.
    Gu, S.
    Liang, B.
    Liao, W.
    ANNALS OF ONCOLOGY, 2021, 32 : S826 - S826
  • [49] Updated results from ALTER-H004 trial: Anlotinib combined with TACE as adjuvant therapy for patients with hepatocellular carcinoma at high risk of recurrence after surgery-A single arm, multi-center, phase II clinical trial
    Wu, Zheng
    Wang, Zheng
    Zhang, Lei
    Song, Xiaojing
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [50] A randomized phase II trial of epigenetic therapy following adjuvant treatment in patients with resected pancreatic cancer and high risk for recurrence.
    Reiss, Kim Anna
    Ahuja, Nita
    Baylin, Stephen
    Mauro, Lauren Ann
    Linden, Sheila
    White, Sharon
    Laheru, Daniel A.
    Herman, Joseph M.
    Wolfgang, Christopher Lee
    Weiss, Matthew J.
    Cameron, John L.
    Makary, Martin
    Azad, Nilofer Saba
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345